ClinicalTrials.gg
Active, not recruitingNCT02180711Updated Sep 28, 2026Results posted

Study of Acalabrutinib Alone or in Combination Therapy in Subjects With B-cell Non-Hodgkin Lymphoma

A Phase 1/2 interventional study of acalabrutinib and rituximab (IV) in Non Hodgkin Lymphoma, sponsored by Acerta Pharma BV. Active, not recruiting at 29 sites in 3 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-28.

Sponsored by Acerta Pharma BV (part of AstraZeneca) · Phase 1/2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
113
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 19 studies in Lymphoma, Non-Hodgkin by AstraZeneca — 3 open to participants now, 6 under way, 2 of them phase 3. Lymphoma, Non-Hodgkin · AstraZeneca.

Enrollment
8th of 18
113 · median 51
Started
2014
with 2 others
Phase 1/2
6 of 19
2 open now
Registered
8th of 19
by date

Among the 19 studies in Lymphoma, Non-Hodgkin by AstraZeneca, this one is the 8th largest by enrollment of the 18 interventional ones that give a count, is one of 3 that started in 2014, is one of 6 in phase 1/2, and was the 8th registered.

Lymphoma, Non-Hodgkin

2,287 studies on the registry are indexed under Lymphoma, Non-Hodgkin; 286 are open to participants now.

Browse Lymphoma, Non-Hodgkin studies →

Open to participants now

3 of the 19 studies in Lymphoma, Non-Hodgkin by AstraZeneca are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

Who these studies take

Of the 245 Lymphoma, Non-Hodgkin studies recruiting now, 145 (59%) set no upper age limit and 77 (31%) stop at 75 or younger; 68 take children under 18; 10 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 19 studies in Lymphoma, Non-Hodgkin by AstraZeneca, or all of them as a file.
02

Study summary

Part 1: To characterize the safety profile of acalabrutinib alone or in combination with rituximab in subjects with R/R FL.

Part 2: To characterize the activity of acalabrutinib alone or in combination with rituximab in subjects with R/R MZL, as measured by ORR.

Part 3: To characterize the safety of acalabrutinib in combination with rituximab and lenalidomide in subjects with R/R FL

Read the detailed description

An Open-label, Phase 1b/2 Study of Acalabrutinib Alone or in Combination Therapy in Subjects with B-cell Non-Hodgkin Lymphoma

03

Conditions studied

  • Non Hodgkin Lymphoma

Keywords

  • Bruton tyrosine kinase inhibitor
  • Btk
  • Follicular Lymphoma
  • FL
  • acalabrutinib
  • ACP-196
  • MZL
  • Marginal Zone Lymphoma
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Men and women ≥ 18 years of age.
  • Part 1: A confirmed diagnosis of FL Grade 1, 2, or 3a, which has after, or been refractory to ≥ 1 prior therapy for FL, or subjects who have not previously received systemic anticancer therapy for FL., and which requires treatment.
  • Part 2: For subject with relapsed or refractory MZL:

confirmed MZL including splenic, nodal, and extranodal sub-types

  1. Subjects with splenic MZL must have an additional , nodal or extranodal, as described in inclusion criterion #4;
  2. Subjects with gastric mucosa-associated lymphoid tissue (MALT) lymphoma must be Helicobacter pylori (HP)-negative

    • Part 3: For subjects with FL: Pathologically confirmed diagnosis of FL Grade 1, 2, or 3a, which has relapsed after, or been refractory to ≥ 1 prior therapy for FL and which requires treatment per National Cancer Institute or ESMO clinical practice guidelines.
    • (ECOG) performance status of ≤ 2.
    • Agreement to use during the study and for 30 days after the last dose of study drugs if sexually active and able to bear or beget children.

Exclusion criteria

Exclusion Criteria:

  • •A life-threatening illness, medical condition or organ system dysfunction which, in the investigator's opinion, could compromise the subject's safety, interfere with the absorption or metabolism of acalabrutinib, or put the study outcomes at undue risk
  • Significant cardiovascular disease such as uncontrolled or symptomatic arrhythmias, congestive heart failure, or myocardial infarction within 6 months of screening, or any Class 3 or 4 cardiac disease as defined by the Functional Classification, or Qtc >480 msec
  • Malabsorption syndrome, disease significantly affecting gastrointestinal function, or resection of the stomach or small bowel, gastric bypass, symptomatic inflammatory bowel disease, or partial or complete bowel obstruction.
  • Breast feeding or pregnant
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
113 participants (actual)

Study arms

  • Experimental
    Part 1: acalabrutinib Regimen 1

    acalabrutinib Regimen 1 for relapsed, refractory Follicular Lymphoma subjects

    Drug: acalabrutinib

  • Experimental
    Part 1: acalabrutinib Regimen 2

    acalabrutinib Regimen 2 + rituximab for relapsed, refractory, or treatment naive Follicular Lymphoma subjects

    Drug: acalabrutinib · Drug: rituximab (IV)

  • Experimental
    Part 2: acalabrutinib Regimen 1

    acalabrutinib Regimen 1 for relapsed, refractory Marginal Zone Lymphoma subjects

    Drug: acalabrutinib

  • Experimental
    Part 2: acalabrutinib Regimen 2

    acalabrutinib Regimen 2 + rituximab for relapsed, refractory Marginal Zone Lymphoma subjects

    Drug: acalabrutinib · Drug: rituximab (IV)

  • Experimental
    Part 3: acalabrutinib Regimen 1

    acalabrutinib Regimen + lenalidomide + rituximab for relapsed, refractory Follicular Lymphoma subjects

    Drug: acalabrutinib · Drug: rituximab (IV) · Drug: Lenalidomide

Interventions

06

What researchers measure

Primary outcomes

  1. Part 1: Incidence of Treatment-emergent Adverse Events.

    Treatment-emergent adverse events were used to characterize the safety profile of acalabrutinib alone or in combination with rituximab in participants with relapsed/refractory follicular lymphoma (R/R FL).

    Time frame: From the first dose of study drug until study discontinuation, 30 days after the last dose of study drug or one day before the first subsequent anticancer therapy, whichever was earlier, up to 80.7 months (the maximum participant's time on this study).

  2. Part 2: Investigator Assessed Objective Response Rate (ORR) According to the Lugano Classification for Non-Hodgkin Lymphoma (NHL).

    The objective response rate (ORR) is used to characterize the activity of acalabrutinib alone or in combination with rituximab in participants with relapsed/refractory marginal zone lymphoma (R/R MZL).

    Time frame: Based on all response assessments since the first dose of study drug until study discontinuation or the initiation of subsequent anticancer therapy, whichever was earlier, up to 65.1 months (the maximum participant's time on this study).

  3. Part 3: Incidence of Treatment-emergent Adverse Events.

    Treatment-emergent adverse events were used to characterize the safety of acalabrutinib in combination with rituximab and lenalidomide in participants with relapsed/refractory follicular lymphoma (R/R FL).

    Time frame: From the first dose of study drug until study discontinuation, 30 days after the last dose of study drug or one day before the first subsequent anticancer therapy, whichever was earlier, up to 54.3 months (the maximum participant's time on this study).

07

Results

Posted Oct 15, 2025

Participant flow

Participant flow — Overall Study
MilestoneP1: RR Acalabrutinib 100 mg BIDP1: RR Acalabrutinib 100 mg BID + RituximabP1: RR Acalabrutinib 200 mg QDP1: TN Acalabrutinib 100 mg BID + RituximabP2: AcalabrutinibP2: Acalabrutinib + RituximabP3: Acalabrutinib + Rituximab + Lenalidomide 15 mgP3: Acalabrutinib + Rituximab + Lenalidomide 20 mg
Started1213213431821
Completed00000000
Not completed1213213431821
Withdrew: Death01007013
Withdrew: Lost to follow-up01001103
Withdrew: Withdrawal by subject21043032
Withdrew: - disease progression01000000
Withdrew: - subject started alternative cancer therapy76220000
Withdrew: - study terminated by sponsor2305320413
Withdrew: - enrolled into follow-up study00010000
Withdrew: - other10010000

Outcome measures

PrimaryPart 1: Incidence of Treatment-emergent Adverse Events.

Treatment-emergent adverse events were used to characterize the safety profile of acalabrutinib alone or in combination with rituximab in participants with relapsed/refractory follicular lymphoma (R/R FL).

Time frame:
From the first dose of study drug until study discontinuation, 30 days after the last dose of study drug or one day before the first subsequent anticancer therapy, whichever was earlier, up to 80.7 months (the maximum participant's time on this study).
Reported as:
Number · Number of participants
Part 1: Incidence of Treatment-emergent Adverse Events.
Number of participantsPart 1: Acalabrutinib 100 mg BIDPart 1: Acalabrutinib 100 mg BID + RituximabPart 1: Relapsed or Refractory Acalabrutinib 200 mg QDPart 1: Acalabrutinib 100 mg Rituximab
Part 1: Incidence of Treatment-emergent Adverse Events.1213213
PrimaryPart 2: Investigator Assessed Objective Response Rate (ORR) According to the Lugano Classification for Non-Hodgkin Lymphoma (NHL).

The objective response rate (ORR) is used to characterize the activity of acalabrutinib alone or in combination with rituximab in participants with relapsed/refractory marginal zone lymphoma (R/R MZL).

Time frame:
Based on all response assessments since the first dose of study drug until study discontinuation or the initiation of subsequent anticancer therapy, whichever was earlier, up to 65.1 months (the maximum participant's time on this study).
Reported as:
Number · Percentage of participants
Part 2: Investigator Assessed Objective Response Rate (ORR) According to the Lugano Classification for Non-Hodgkin Lymphoma (NHL).
Percentage of participantsPart 2: AcalabrutinibPart 2: Acalabrutinib + Rituximab
Part 2: Investigator Assessed Objective Response Rate (ORR) According to the Lugano Classification for Non-Hodgkin Lymphoma (NHL).60.5 (44.4 to 75.0)0 (0 to 97.5)
PrimaryPart 3: Incidence of Treatment-emergent Adverse Events.

Treatment-emergent adverse events were used to characterize the safety of acalabrutinib in combination with rituximab and lenalidomide in participants with relapsed/refractory follicular lymphoma (R/R FL).

Time frame:
From the first dose of study drug until study discontinuation, 30 days after the last dose of study drug or one day before the first subsequent anticancer therapy, whichever was earlier, up to 54.3 months (the maximum participant's time on this study).
Reported as:
Number · Number of participants
Part 3: Incidence of Treatment-emergent Adverse Events.
Number of participantsPart 3: Acalabrutinib + Rituximab + Lenalidomide 15 mgPart3: Acalabrutinib + Rituximab + Lenalidomide+20mg
Part 3: Incidence of Treatment-emergent Adverse Events.821

Adverse events

Collected over Treatment-emergent period, i.e. from the first dose of study drug until study discontinuation, 30 days after the last dose of study drug, or one day before the initiation of the subsequent anticancer therapy, whichever occurred earlier, up to 80.7 months for part 1, up to 65.1 months for part 2, and up to 54.3 months for part 3.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
P1: RR Acalabrutinib 100 mg BID0/12 (0%)2/12 (16.7%)12/12 (100%)
P1: RR Acalabrutinib 100 mg BID + Rituximab1/13 (7.7%)5/13 (38.5%)13/13 (100%)
P1: RR Acalabrutinib 200 mg QD0/2 (0%)0/2 (0%)2/2 (100%)
P1: TN Acalabrutinib 100 mg BID + Rituximab0/13 (0%)3/13 (23.1%)13/13 (100%)
P2: Acalabrutinib7/43 (16.3%)9/43 (20.9%)41/43 (95.3%)
P2: Acalabrutinib + Rituximab0/1 (0%)1/1 (100%)1/1 (100%)
P3: Acalabrutinib + Rituximab + Lenalidomide 15 mg1/8 (12.5%)4/8 (50%)8/8 (100%)
P3: Acalabrutinib + Rituximab + Lenalidomide 20 mg3/21 (14.3%)11/21 (52.4%)21/21 (100%)
Most frequent serious events
Showing 10 of 46
Most frequent serious events
EventP1: RR Acalabrutinib 100 mg BIDP1: RR Acalabrutinib 100 mg BID + RituximabP1: RR Acalabrutinib 200 mg QDP1: TN Acalabrutinib 100 mg BID + RituximabP2: AcalabrutinibP2: Acalabrutinib + RituximabP3: Acalabrutinib + Rituximab + Lenalidomide 15 mgP3: Acalabrutinib + Rituximab + Lenalidomide 20 mg
SepsisInfections and infestations0/120/130/20/130/431/10/82/21
Covid-19 pneumoniaInfections and infestations0/120/130/20/130/430/10/84/21
PneumoniaInfections and infestations1/120/130/20/131/430/10/83/21
Pneumonia influenzalInfections and infestations0/120/130/20/130/430/11/80/21
DehydrationMetabolism and nutrition disorders0/120/130/20/130/430/11/80/21
AphasiaNervous system disorders0/120/130/20/130/430/11/80/21
Chronic obstructive pulmonary diseaseRespiratory, thoracic and mediastinal disorders0/120/130/20/131/430/11/80/21
Duodenal ulcerGastrointestinal disorders0/120/130/20/130/430/11/80/21
Covid-19Infections and infestations0/120/130/20/131/430/11/82/21
Colon cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/120/130/20/130/430/10/80/21
Most frequent other events
Showing 10 of 246
Most frequent other events
EventP1: RR Acalabrutinib 100 mg BIDP1: RR Acalabrutinib 100 mg BID + RituximabP1: RR Acalabrutinib 200 mg QDP1: TN Acalabrutinib 100 mg BID + RituximabP2: AcalabrutinibP2: Acalabrutinib + RituximabP3: Acalabrutinib + Rituximab + Lenalidomide 15 mgP3: Acalabrutinib + Rituximab + Lenalidomide 20 mg
Blood creatinine increasedInvestigations1/121/130/20/138/431/11/82/21
Haemoglobin decreasedInvestigations0/120/130/20/130/431/10/80/21
White blood cell count decreasedInvestigations0/120/130/21/130/431/10/83/21
Decreased appetiteMetabolism and nutrition disorders2/123/130/21/134/431/11/84/21
HeadacheNervous system disorders7/125/130/26/1315/431/13/88/21
DyspnoeaRespiratory, thoracic and mediastinal disorders3/122/131/22/135/431/11/86/21
AlopeciaSkin and subcutaneous tissue disorders0/121/130/21/134/431/10/81/21
Ingrowing nailSkin and subcutaneous tissue disorders0/120/130/20/130/431/10/80/21
PruritusSkin and subcutaneous tissue disorders1/122/130/22/133/431/13/86/21
UrticariaSkin and subcutaneous tissue disorders1/120/130/20/130/431/10/80/21

Baseline characteristics

The All-treated Population, defined as all subjects who received at least 1 dose of study treatment.

Age, Continuous
Age, Continuous(Years)P1: RR Acalabrutinib 100 mg BIDP1: RR Acalabrutinib 100 mg BID + RituximabP1: RR Acalabrutinib 200 mg QDP1: TN Acalabrutinib 100 mg BID + RituximabP2: AcalabrutinibP2: Acalabrutinib + RituximabP3: Acalabrutinib + Rituximab + Lenalidomide 15 mgP3: Acalabrutinib + Rituximab + Lenalidomide 20 mgTotal
Mean63.3 ± 16.066.7 ± 10.659.0 ± 21.259.6 ± 12.266.0 ± 10.043.0 ± NA62.5 ± 9.763.0 ± 9.764.0 ± 11.2
Sex: Female, Male
Sex: Female, Male(Participants)P1: RR Acalabrutinib 100 mg BIDP1: RR Acalabrutinib 100 mg BID + RituximabP1: RR Acalabrutinib 200 mg QDP1: TN Acalabrutinib 100 mg BID + RituximabP2: AcalabrutinibP2: Acalabrutinib + RituximabP3: Acalabrutinib + Rituximab + Lenalidomide 15 mgP3: Acalabrutinib + Rituximab + Lenalidomide 20 mgTotal
Female68181711648
Male651526071565
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)P1: RR Acalabrutinib 100 mg BIDP1: RR Acalabrutinib 100 mg BID + RituximabP1: RR Acalabrutinib 200 mg QDP1: TN Acalabrutinib 100 mg BID + RituximabP2: AcalabrutinibP2: Acalabrutinib + RituximabP3: Acalabrutinib + Rituximab + Lenalidomide 15 mgP3: Acalabrutinib + Rituximab + Lenalidomide 20 mgTotal
Hispanic or Latino0201103310
Not Hispanic or Latino1211212411517101
Not Reported000010012
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)P1: RR Acalabrutinib 100 mg BIDP1: RR Acalabrutinib 100 mg BID + RituximabP1: RR Acalabrutinib 200 mg QDP1: TN Acalabrutinib 100 mg BID + RituximabP2: AcalabrutinibP2: Acalabrutinib + RituximabP3: Acalabrutinib + Rituximab + Lenalidomide 15 mgP3: Acalabrutinib + Rituximab + Lenalidomide 20 mgTotal
Asian000100012
Black or African American100040027
Not Reported000010113
White1113212381717101
Region of Enrollment
Region of Enrollment(Participants)P1: RR Acalabrutinib 100 mg BIDP1: RR Acalabrutinib 100 mg BID + RituximabP1: RR Acalabrutinib 200 mg QDP1: TN Acalabrutinib 100 mg BID + RituximabP2: AcalabrutinibP2: Acalabrutinib + RituximabP3: Acalabrutinib + Rituximab + Lenalidomide 15 mgP3: Acalabrutinib + Rituximab + Lenalidomide 20 mgTotal
Canada000040059
Italy000030003
United States1213213361816101
08

Study locations

29 sites
  • Research Site
    Tucson, Arizona 85719, United States
  • Research Site
    Downey, California 90241, United States
  • Research Site
    Duarte, California 91010, United States
  • Research Site
    Fountain Valley, California 92708, United States
  • Research Site
    Santa Monica, California 90404, United States
  • Research Site
    Coral Gables FL, Florida 33146, United States
  • Research Site
    Chicago, Illinois 60611, United States
  • Research Site
    Chicago, Illinois 60612, United States
  • Research Site
    Chicago, Illinois 60637, United States
  • Research Site
    Louisville, Kentucky 40207, United States
  • Research Site
    New Orleans, Louisiana 70112, United States
  • Research Site
    Ann Arbor, Michigan 48109, United States
  • Research Site
    Morristown, New Jersey 07960, United States
  • Research Site
    Lake Success, New York 11042, United States
  • Research Site
    New York, New York 10021, United States
  • Research Site
    Columbus, Ohio 43210, United States
  • Research Site
    Greenville, South Carolina 29615, United States
  • Research Site
    Dallas, Texas 75235, United States
  • Research Site
    Houston, Texas 77030, United States
  • Research Site
    San Antonio, Texas 78217, United States
  • Research Site
    Temple, Texas 76508, United States
  • Research Site
    Salt Lake City, Utah 84112, United States
  • Research Site
    Spokane, Washington 99208, United States
  • Research Site
    Edmonton, Alberta t6G1Z2, Canada
  • Research Site
    London, Ontario N6A 5W9, Canada
  • Research Site
    Toronto, Ontario M5G 2M9, Canada
  • Research Site
    Bologna, 40138, Italy
  • Research Site
    Milan, 20132, Italy
  • Research Site
    Palermo, 90146, Italy
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2014 to primary completion in Aug 2023, 103 months.

Results were first posted in Oct 2025, 2 years 1 month after primary completion.

Of 69 industry-sponsored phase 1/2 interventional studies under Lymphoma, Non-Hodgkin, half reached primary completion within 65 months of starting (the median), counting those still running; a quarter within 40 and three quarters within 103. This study's 103 months is above that.

Counting every sponsor, half of 135 studies reached it within 72 months; a quarter within 50 and three quarters within 104.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 30, 2014
First posted
Jul 3, 2014
StartActual
Dec 29, 2014
Primary completionActual
Aug 25, 2023
CompletionEst.
Dec 11, 2028
Results first posted
Oct 15, 2025
Last update
Sep 28, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Minor edits
Nothing that changes what the study is or who can join. Edited: registry notes, identifiers and verification date
1 update, last Sep 28, 2026
Show all 1 update
  1. Sep 28, 2026
    Minor edits only
    + 3 other changes: registry notes, identifiers and verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT02180711
Lead sponsor
Acerta Pharma BV
Collaborators
AstraZeneca
Responsible party
Sponsor
First posted
Jul 3, 2014
Start date
Dec 29, 2014
Primary completion
Aug 25, 2023
Completion
Dec 11, 2028 (estimated)
Results posted
Oct 15, 2025
Last update
Sep 28, 2026

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Acalabrutinib

Start the discussion